omniture

How Digital Transformation is Changing Asia's Biopharma Landscape -- An Invitation to Attend Biopharma Asia Convention Keynote Plenary

2017-03-06 09:00

SINGAPORE, March 6, 2017 /PRNewswire/ -- Leading innovators Prenetics, Fenbushi Venture Capital and Human Longevity will lead BioPharma Asia Convention 2017 in the opening keynote plenary on 22 March 2017 at Suntec Convention Centre, Singapore.

KEYNOTE SESSION 1: The future of healthcare: Genomics and its impact on patients, pharma, physicians and regulators

In the digital age, with technology changing so rapidly, how can we make sure that we are prepared for the future? This exciting opening address for BioPharma Asia 2017 will explore the most exciting trends, ideas and technologies driving the future of our industry, including practical advice on how you can brace your business for the times ahead.

Danny Yeung, CEO, Prenetics, Founding Partner, SXE Venture

KEYNOTE SESSION 2: Blockchain meets Biopharma: How to prepare for the global data evolution

When you hear blockchain, you don't necessarily think biopharmaceuticals. But the applications of blockchain can do so much more than digital currency. For example, it can help increase the efficiency of the drug development process, by providing better security and transparency. It allows you to indelibly record medicinal and genomic data to combat counterfeit pharmaceutical production and protect intellectual property. That's just a few applications. Join us as we uncover more and also consider some of the potential challenges that could be created, for example, around compliance and privacy.

Vitalik Buterin, Co-Founder Ethereum, General Partner, Fenbushi Venture Capital

KEYNOTE SESSION 3: Redesigning healthcare system with genomics, technology driven drug discovery

Advances in next generation sequencing (NGS) technologies over the last decade are beginning to have an impact on the amount and depth of sequencing data available to researchers in the pharmaceutical industry. In target identification and validation, the availability of human genetic data to link the target to the disease, can mean the difference between success and failure in phase II clinical trials. In this presentation, various techniques and drug discovery platforms will be discussed to help companies in improving efficiency of drug delivery products to drive the pharma industry towards the goal of personalized medicine.

Suzanne Brewerton, Group Leader of Bioinformatics, Human Longevity, Singapore

130 other pharma leaders are confirmed to speak at the BioPharma Asia Convention 2017 across 5 conferences - view more details.

About BioPharma Asia Convention 2017
Date: 22 -23 March 2017
Conference opening hours: 09:00 am
Venue: Level 4, Hall 404-406, Suntec Singapore International Convention & Exhibition Centre
Website:  www.terrapinn.com/bioasia

About Terrapinn
Terrapinn is a business media company. Its products are trade exhibitions, conferences, training solutions and electronic and print publications. For more information, please visit www.terrapinn.com.

Note: Press registration for the conference is compulsory and advance scheduling for speaker/ sponsor interviews is recommended. Final issuance of press passes is subjected to Terrapinn's discretion.  For your press pass, please contact the following:

Mildred Ang, Marketing Manager
Tel: +65 6322 2769
mildred.ang@terrapinn.com

Source: BioPharma Asia Convention 2017, Terrapinn